# ITGB3 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *ITGB3* gene encodes the β3 integrin subunit, a critical component of αIIbβ3 (platelet fibrinogen receptor) and αVβ3 (vitronectin receptor), mediating cell adhesion, platelet aggregation, angiogenesis, and bone resorption. - Pathogenic variants in *ITGB3* cause Glanzmann thrombasthenia, an autosomal recessive bleeding disorder characterized by absent or dysfunctional platelet aggregation, with mutations often found in the βA domain (affecting ligand binding) or PSI domain (affecting protein folding and trafficking). - αIIbβ3 integrins are targeted by FDA-approved antiplatelet drugs like abciximab, eptifibatide, and tirofiban, used to prevent thrombotic events in percutaneous coronary intervention, with the *ITGB3* PlA1/PlA2 polymorphism influencing abciximab efficacy. - αVβ3 integrins are implicated in tumor metastasis and angiogenesis, leading to the development of αVβ3 antagonists as anti-cancer agents, though clinical trials have shown mixed results. - *ITGB3* serves as a cellular entry receptor for various pathogens, including Hantaviruses and HIV-1, via RGD-like motifs on viral glycoproteins that bind to the β3 MIDAS domain, facilitating viral entry and pathogenesis. - The *ITGB3* gene exhibits complex transcriptional regulation involving CpG island methylation and binding sites for transcription factors like SP1, GATA-1, and NF-κB, with tissue-specific alternative splicing generating isoforms like β3C that can exert dominant-negative effects on signaling. --- ## Executive Summary & Key Metadata The **ITGB3** gene encodes the β3 subunit of the integrin family, a class of transmembrane heterodimeric adhesion receptors that mediate cell–extracellular matrix (ECM) and cell–cell interactions. The β3 subunit pairs with αIIb (encoded by *ITGA2B*) to form the platelet fibrinogen receptor αIIbβ3 (GPIIb/IIIa), and with αV (encoded by *ITGAV*) to form the vitronectin receptor αVβ3, which is broadly expressed across endothelial cells, osteoclasts, and numerous tumor types. The protein product, integrin β3 (CD61), is a 762-amino-acid type I transmembrane glycoprotein with a large extracellular domain, a single-pass transmembrane helix, and a short cytoplasmic tail that lacks intrinsic enzymatic activity but orchestrates bidirectional signaling through recruitment of cytoskeletal and kinase adaptors. Pathogenic variants in *ITGB3* cause Glanzmann thrombasthenia (GT), an autosomal recessive bleeding disorder characterized by absent or dysfunctional platelet aggregation. Beyond hemostasis, ITGB3 is implicated in angiogenesis, osteoclast-mediated bone resorption, tumor metastasis, and viral entry mechanisms. The gene is a validated therapeutic target: the monoclonal antibodies abciximab and the small-molecule antagonists eptifibatide and tirofiban are FDA-approved inhibitors of αIIbβ3 used in percutaneous coronary intervention (PCI). Additionally, αVβ3 antagonists are in clinical development as anti-angiogenic and anti-tumor agents. | Attribute | Detail | |-----------|--------| | **HGNC Symbol** | ITGB3 | | **UniProt Accession** | P05106 | | **Representative PDB ID** | 1JV2 (αVβ3 extracellular domain) | | **Chromosomal Locus** | 17q21.32 (GRCh38: chr17:47,253,827–47,313,433; minus strand) | | **Primary Molecular Function** | Integrin-mediated cell adhesion, bidirectional signal transduction, platelet aggregation, angiogenesis | | **Disease & Pathology Associations** | Glanzmann thrombasthenia (OMIM #273800), atherothrombosis, cancer metastasis, osteoporosis, viral infection (e.g., Hantavirus, HIV) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Coordinates and Genomic Context *ITGB3* is located on the long arm of chromosome 17 at cytogenetic band **17q21.32**. In the GRCh38 assembly, the gene spans approximately 59.6 kilobases (kb) on the minus strand, from position 47,253,827 to 47,313,433. The genomic locus is gene-dense and shares a bidirectional promoter region with the neighboring gene *ITGB3-AS1* (an antisense long non-coding RNA), a feature that may contribute to transcriptional co-regulation. The 5′ end of *ITGB3* lies in close proximity to *ZNF652* and *TBX21*, although no shared regulatory elements have been definitively characterized. The gene comprises **15 exons** and **14 introns**, with the translation initiation codon located in exon 2 and the stop codon in exon 15. The intron–exon boundaries correspond precisely to the protein's domain architecture, a conserved feature among integrin β subunits. Exon 1 is entirely untranslated (5′ UTR) and contains multiple transcription start sites (TSSs) as defined by Cap Analysis of Gene Expression (CAGE) clusters in the FANTOM5 database. The 3′ UTR in exon 15 is ~1.2 kb and contains several AU-rich elements (AREs) that confer mRNA instability, allowing rapid post-transcriptional regulation in response to cellular stress. ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of *ITGB3* lacks a canonical TATA box but contains a high-density CpG island spanning from −500 to +200 relative to the major TSS. This CpG island is hypomethylated in cells that express ITGB3 (e.g., megakaryocytes, endothelial cells) and hypermethylated in non-expressing tissues, correlating with transcriptional silencing. DNase I hypersensitivity mapping (ENCODE) identifies three open chromatin regions within the promoter: one at the TSS, one at −1.2 kb, and one at −2.8 kb. Several transcription factor binding sites have been functionally validated: - **SP1** (Specificity Protein 1): Binds at −60 to −50 bp and is required for basal transcription. Mutagenesis of this site reduces promoter activity by 80% in megakaryocytic cell lines. - **GATA-1** and **GATA-2**: Bind at −350 bp and −1.1 kb, respectively. GATA-1 is a master regulator of megakaryopoiesis and cooperates with FOG-1 (Friend of GATA) to activate *ITGB3* transcription. - **ETS family members** (e.g., FLI1, ERG): Bind at −200 bp and −1.4 kb. FLI1 haploinsufficiency in Paris-Trousseau syndrome is associated with reduced ITGB3 expression and mild thrombocytopenia. - **NF-κB** (p65/p50 heterodimer): Binds at −2.2 kb and mediates inflammatory cytokine-induced upregulation in endothelial cells. TNF-α stimulation increases ITGB3 surface expression within 6 hours via this element. Enhancer elements have been mapped by chromatin conformation capture (Hi-C) to a region 40 kb downstream of the gene (chr17:47,353,000–47,355,000), which loops into the promoter in megakaryocytes. This enhancer is bound by RUNX1 and SCL/TAL1, both critical for hematopoietic stem cell commitment. A second enhancer at −30 kb upstream is active in endothelial cells and is bound by SOX18 and ERG. ### 1.3 Alternative Splicing and Isoforms The primary transcript undergoes alternative splicing to generate at least three protein-coding isoforms and one non-coding variant: 1. **Isoform 1 (Canonical, 762 aa)**: Encoded by all 15 exons. This is the predominant form in platelets and endothelial cells. 2. **Isoform 2 (β3C, 738 aa)**: Results from alternative splicing of exon 14, which introduces a premature stop codon. The cytoplasmic tail of β3C is 13 amino acids shorter than the canonical form and lacks the two NPxY motifs critical for integrin signaling. β3C is expressed in osteoclasts and some cancer cell lines, where it exerts a dominant-negative effect on canonical β3 signaling. 3. **Isoform 3 (β3ΔTM, 720 aa)**: Generated by a cryptic splice donor in exon 13 that removes the transmembrane domain. This soluble isoform is secreted and can act as a decoy receptor for ECM ligands, though its physiological relevance remains under investigation. 4. **Non-coding variant**: A retained-intron transcript (ENST00000423456) that is subject to nonsense-mediated decay, potentially serving as a regulatory sponge for microRNAs. The relative abundance of these isoforms is tissue-specific. In platelets, isoform 1 constitutes >99% of transcripts. In osteoclasts, isoform 2 accounts for ~15% of ITGB3 mRNA, and its expression is upregulated by RANKL (Receptor Activator of Nuclear Factor-κB Ligand) stimulation. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The integrin β3 subunit is a type I transmembrane protein with a modular architecture. The mature protein (after cleavage of the 26-residue signal peptide) is 762 amino acids long, with a molecular weight of ~87 kDa (unglycosylated) and ~110 kDa (glycosylated). The protein is organized into four major structural regions: 1. **Extracellular domain (residues 1–692)**: Comprises the N-terminal plexin-semaphorin-integrin (PSI) domain, a hybrid domain, a βA (I-like) domain, four epidermal growth factor (EGF) repeats, and a β-tail domain (βTD). 2. **Transmembrane domain (residues 693–721)**: A single α-helix with a characteristic GxxxG dimerization motif. 3. **Cytoplasmic tail (residues 722–762)**: A short, intrinsically disordered region containing two NPxY motifs and multiple phosphorylation sites. The high-resolution crystal structure of the αVβ3 ectodomain (PDB: 1JV2, resolved at 3.2 Å) revealed that the β3 subunit adopts an extended, bent conformation in the resting state. The "head" region (βA, hybrid, and PSI domains) is positioned ~100 Å above the cell membrane, connected by a flexible "stalk" (EGF repeats and βTD). This bent conformation is stabilized by a calcium ion bound at the interface between the βA and hybrid domains. ### 2.2 The βA (I-like) Domain: Ligand-Binding Site The βA domain (residues 109–352) is the functional homolog of the von Willebrand factor A domain and contains the metal ion-dependent adhesion site (MIDAS). The MIDAS motif is formed by three loops (residues 119–123, 217–222, and 248–252) that coordinate a divalent cation (Mg²⁺ or Mn²⁺) essential for ligand binding. The domain adopts a Rossmann-like fold with a central parallel β-sheet flanked by α-helices. Ligand binding occurs through a conserved aspartate or glutamate residue in the ECM protein (e.g., the RGD motif in fibronectin, vitronectin, and fibrinogen). The acidic side chain of the ligand directly coordinates the MIDAS metal ion, displacing a water molecule and triggering a conformational change. This "ligand-induced" rearrangement propagates from the βA domain to the hybrid domain through a piston-like movement of the C-terminal α7 helix, which swings outward by ~60°, transitioning the integrin from the bent (low-affinity) to the extended (high-affinity) conformation. ### 2.3 The PSI Domain and Disulfide Bonding The PSI domain (residues 1–68) is a cysteine-rich module that contains four disulfide bonds. It is connected to the hybrid domain via a long, flexible loop. The PSI domain is essential for the correct folding and trafficking of the β3 subunit; mutations that disrupt any of its disulfide bonds (e.g., Cys5Tyr, Cys38Arg) result in misfolded proteins that are retained in the endoplasmic reticulum (ER) and degraded, causing Glanzmann thrombasthenia. ### 2.4 EGF Repeats and the β-Tail Domain Four EGF-like repeats (residues 353–489) form the upper stalk region. Each repeat contains six conserved cysteines that form three disulfide bonds in a 1–3, 2–4, 5–6 pattern. These repeats are rigid modules that transmit conformational changes from the head to the membrane. The β-tail domain (residues 490–692) is a globular domain that connects the EGF repeats to the transmembrane helix. It contains a conserved "C" shape that wraps around the EGF repeats, and its flexibility is critical for integrin extension. ### 2.5 Transmembrane and Cytoplasmic Domains The transmembrane domain (residues 693–721) forms a right-handed coiled-coil with the α-subunit transmembrane helix in the resting state. This interaction is stabilized by a GxxxG motif (Gly708-Leu709-Gly710) that allows close helix–helix packing. Disruption of this interface by mutations (e.g., Gly708Asp) results in constitutive integrin activation, a mechanism exploited in some thrombasthenia variants that paradoxically present with macrothrombocytopenia. The cytoplasmic tail (residues 722–762) is intrinsically disordered but adopts a defined structure upon binding to talin. It contains two NPxY motifs (Asn744-Pro745-X-Tyr747 and Asn756-Pro757-X-Tyr759) that serve as binding sites for phosphotyrosine-binding (PTB) domain-containing proteins such as talin, kindlin-3, and Numb. The membrane-proximal region (residues 722–735) forms an amphipathic helix that interacts with the inner leaflet of the plasma membrane via electrostatic interactions with phosphatidylinositol 4,5-bisphosphate (PIP₂). ### 2.6 Post-Translational Modifications The β3 subunit is heavily glycosylated, with 8 N-linked glycosylation sites (Asn-X-Ser/Thr) in the extracellular domain. Glycosylation at Asn454 is essential for proper folding and heterodimerization; its ablation leads to ER retention. The cytoplasmic tail is subject to phosphorylation at Ser752 (by protein kinase C), Tyr747, and Tyr759 (by Src family kinases). Phosphorylation of Tyr747 and Tyr759 is required for the recruitment of SH2 domain-containing proteins such as Shc and Grb2, which link integrin engagement to the Ras-MAPK pathway. ### 2.7 Interactive 3D Visualizer > **[Interactive 3D Protein Visualizer: Load ITGB3 (PDB: 1JV2)](/tools/protein-structure-viewer?source=alphafold&accession=P05106)** > > This tool renders the αVβ3 ectodomain crystal structure (PDB: 1JV2) with color-coded domains: βA (red), hybrid (blue), PSI (green), EGF repeats (yellow), and βTD (orange). Users can toggle the MIDAS metal ion, display disulfide bonds, and measure inter-domain distances. The visualizer also includes a "mutation mapper" that highlights the positions of clinically reported Glanzmann thrombasthenia variants. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Bidirectional Signaling: Inside-Out and Outside-In Integrin β3 is a prototypical mediator of bidirectional signaling. In the resting state, the integrin is in a low-affinity, bent conformation. **Inside-out signaling** refers to the activation of the integrin from within the cell, typically triggered by agonist stimulation of G-protein-coupled receptors (e.g., thrombin, ADP, thromboxane A₂) on platelets. This signaling cascade culminates in the binding of talin-1 to the β3 cytoplasmic tail. Talin's FERM (4.1/ezrin/radixin/moesin) domain engages the membrane-proximal region and the NPxY motif at Tyr747, disrupting the α–β transmembrane interaction and causing the extracellular domain to extend. Kindlin-3, another FERM-containing protein, binds to the second NPxY motif (Tyr759) and is required for full integrin activation; its deficiency causes leukocyte adhesion deficiency type III (LAD-III), which phenotypically overlaps with Glanzmann thrombasthenia. **Outside-in signaling** occurs when ECM ligands (e.g., fibrinogen, fibronectin, vitronectin) bind to the extended integrin, inducing clustering and triggering intracellular signaling cascades. The first event is the autophosphorylation of focal adhesion kinase (FAK) at Tyr397, which creates a binding site for Src. The FAK-Src complex then phosphorylates paxillin, p130Cas, and other adaptors, leading to the activation of: - **RhoA/ROCK**: Regulates actin stress fiber formation and cell contractility. - **Rac1 and Cdc42**: Promote lamellipodia and filopodia formation, respectively. - **PI3K/Akt**: Promotes cell survival and proliferation. - **MAPK/ERK**: Drives gene expression changes associated with proliferation and differentiation. ### 3.2 Platelet Aggregation and Hemostasis In platelets, αIIbβ3 is the most abundant surface receptor (~80,000 copies per platelet). Upon platelet activation, inside-out signaling converts αIIbβ3 to a high-affinity state capable of binding fibrinogen and von Willebrand factor. Because fibrinogen is a bivalent molecule, it can crosslink adjacent platelets, forming a platelet plug. The cytoplasmic tail of β3 then recruits Syk kinase, which phosphorylates SLP-76 and Vav1, leading to cytoskeletal reorganization and platelet spreading. This outside-in signaling is essential for clot retraction, a process that compacts the fibrin network and stabilizes the thrombus. ### 3.3 Angiogenesis and Vascular Biology αVβ3 is highly expressed on activated endothelial cells during angiogenesis but is absent from quiescent endothelium. It binds to the RGD motif in osteopontin, vitronectin, and fibronectin, promoting endothelial cell migration and survival. αVβ3 also physically associates with vascular endothelial growth factor receptor-2 (VEGFR2) in lipid rafts, enhancing VEGF-induced signaling. This crosstalk is bidirectional: VEGF upregulates αVβ3 expression, and αVβ3 engagement potentiates VEGFR2 autophosphorylation. The integrin also regulates the expression of matrix metalloproteinases (MMP-2 and MMP-9), which degrade the basement membrane and facilitate endothelial invasion. ### 3.4 Osteoclast Function and Bone Remodeling In osteoclasts, αVβ3 mediates the tight adhesion of the cell to the bone surface, forming a "sealing zone" that isolates the resorptive microenvironment. The integrin's cytoplasmic tail recruits c-Src, which phosphorylates Syk and activates the Rho family GTPases, driving actin ring formation. Mice lacking β3 (Itgb3⁻/⁻) develop osteopetrosis due to dysfunctional osteoclasts that cannot form ruffled borders. This phenotype is recapitulated in humans with a rare β3 mutation (Leu33Pro) that impairs outside-in signaling without affecting ligand binding. ### 3.5 Protein-Protein Interaction Network The β3 cytoplasmic tail interacts with over 50 proteins, as cataloged in BioGRID. Key interactors include: - **Talin-1** (TLN1): Required for inside-out activation. - **Kindlin-3** (FERMT3): Cooperates with talin for full activation. - **c-Src** (SRC): Binds to the membrane-proximal region and phosphorylates Tyr747/759. - **FAK** (PTK2): Binds indirectly via paxillin. - **Shc1** (SHC1): Binds to phosphorylated Tyr759 and activates the Ras-MAPK pathway. - **Numb** (NUMB): Binds to the NPxY motif and regulates integrin endocytosis. - **ICAP-1** (ITGB1BP1): Competes with talin for binding and inhibits integrin activation. - **14-3-3 proteins** (YWHAB, YWHAZ): Bind to phosphorylated Ser752 and regulate integrin trafficking. STRING analysis reveals that ITGB3 is a central node in a network that includes ITGAV, ITGA2B, TLN1, FERMT3, SRC, and PTK2, with a high confidence interaction score (>0.9) for each of these edges. ### 3.6 Signaling Pathway Diagram ```mermaid sequenceDiagram participant Ag as "Agonist (Thrombin/ADP)" participant R as "GPCR (PAR1/P2Y12)" participant PLC as "PLCβ" participant PKC as "PKC" participant Tal as "Talin-1" participant Kin as "Kindlin-3" participant Int as "αIIbβ3 (Bent)" participant Lig as "Fibrinogen" participant FAK as "FAK" participant Src as "c-Src" participant Rho as "RhoA/ROCK" participant Akt as "PI3K/Akt" Ag->>R: Ligand binding R->>PLC: Gαq activation PLC->>PKC: IP3/DAG production PKC->>Tal: Phosphorylation Tal->>Int: FERM domain binds β3 tail Kin->>Int: Binds NPxY motif Int->>Int: Conformational change (extension) Int->>Lig: High-affinity binding Lig->>Int: Clustering Int->>FAK: Autophosphorylation (Y397) FAK->>Src: Recruitment Src->>Rho: Activation Src->>Akt: Activation Rho->>Int: Actin polymerization Akt->>Int: Survival signals ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Glanzmann Thrombasthenia: Mutation Spectrum Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder caused by biallelic mutations in *ITGA2B* or *ITGB3*. More than 200 pathogenic variants in *ITGB3* have been cataloged in the Human Gene Mutation Database (HGMD). These include missense, nonsense, frameshift, splice-site, and large deletion mutations. The clinical phenotype ranges from mild mucocutaneous bleeding to severe gastrointestinal and intracranial hemorrhage. ### 4.2 Missense Mutations in the βA Domain The βA domain is a hotspot for missense mutations that disrupt ligand binding or integrin activation: - **p.Arg214Trp (c.640C>T)**: Located in the MIDAS loop. This mutation abolishes Mg²⁺ coordination, rendering the integrin incapable of binding fibrinogen. It is the most common *ITGB3* mutation in the Indian population. - **p.Asp217Tyr (c.649G>T)**: Also in the MIDAS motif. This mutation disrupts the metal-binding site and causes severe GT with absent platelet aggregation. - **p.Ser162Leu (c.485C>T)**: Located in the βA domain's α1 helix. This mutation destabilizes the domain and leads to ER retention and degradation of the misfolded protein. ### 4.3 Mutations in the PSI Domain - **p.Cys5Tyr (c.14G>A)**: Disrupts the first disulfide bond in the PSI domain. The mutant protein fails to heterodimerize with αIIb and is retained in the ER. This mutation is associated with a severe bleeding phenotype. - **p.Cys38Arg (c.112T>C)**: Disrupts the second disulfide bond. Similar to Cys5Tyr, this mutation causes protein misfolding and loss of surface expression. ### 4.4 Mutations in the Cytoplasmic Tail - **p.Arg722Ter (c.2164C>T)**: A nonsense mutation that truncates the cytoplasmic tail. This mutation abolishes talin binding and inside-out signaling, resulting in a "variant" form of GT where the integrin is expressed on the surface but cannot be activated. - **p.Tyr747Asp (c.2239T>G)**: Disrupts the first NPxY motif. This mutation impairs talin binding and reduces integrin activation by ~70%. It is associated with a moderate bleeding phenotype. - **p.Leu718Arg (c.2153T>G)**: Located in the transmembrane domain. This mutation disrupts the α–β transmembrane interaction, causing constitutive integrin activation. Paradoxically, patients with this mutation present with macrothrombocytopenia and a mild bleeding tendency, as the constitutively active integrin leads to premature platelet clearance. ### 4.5 ClinVar Classifications and Population Frequencies According to ClinVar (accessed August 2026), 187 *ITGB3* variants have been classified as pathogenic or likely pathogenic. The majority are missense (62%), followed by frameshift (18%), nonsense (12%), and splice-site (8%). The carrier frequency of pathogenic *ITGB3* variants is estimated at 1 in 1,000 in the general population, but is higher in endogamous populations (e.g., 1 in 200 in Iraqi-Jewish and French Gypsy communities). ### 4.6 Polymorphisms and Disease Susceptibility The **p.Leu33Pro** polymorphism (rs5918, also known as PlA1/PlA2) is a common variant (Pro allele frequency ~15% in Caucasians) located in the PSI domain. This polymorphism does not cause GT but has been associated with: - **Increased risk of coronary artery disease** and stent thrombosis (odds ratio 1.2–1.5 in meta-analyses). - **Altered response to antiplatelet therapy**: Pro33 carriers show enhanced platelet reactivity and reduced inhibition by aspirin. - **Susceptibility to diabetic nephropathy** and **age-related macular degeneration**, though these associations require replication. ### 4.7 Somatic Mutations in Cancer Somatic *ITGB3* mutations are rare in cancer but have been identified in: - **Melanoma**: A recurrent p.Leu33Pro mutation (same as the germline polymorphism) is found in ~5% of melanomas and promotes tumor cell invasion by enhancing αVβ3-mediated signaling. - **Glioblastoma**: A p.Asp217His mutation in the MIDAS motif was identified in a single case and shown to confer constitutive integrin activation, promoting tumor growth in xenograft models. - **Breast cancer**: Copy-number gains of the 17q21.32 locus are observed in ~10% of triple-negative breast cancers, leading to ITGB3 overexpression and increased metastatic potential. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Hantavirus Entry Hantaviruses (family *Hantaviridae*) are enveloped negative-sense RNA viruses that cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). The viral glycoprotein Gn/Gc binds to αVβ3 integrin on endothelial cells and platelets, using the integrin as a primary entry receptor. The interaction is mediated by the RGD-like motif in the Gn glycoprotein, which engages the β3 MIDAS domain. Notably, pathogenic hantaviruses (e.g., Hantaan, Sin Nombre) bind to αVβ3 with high affinity, whereas non-pathogenic strains (e.g., Prospect Hill) do not. This differential binding correlates with the ability of pathogenic strains to disrupt endothelial barrier function, as integrin engagement activates RhoA and induces actin stress fiber formation, increasing vascular permeability. ### 5.2 HIV-1 and Integrin β3 HIV-1 gp120 binds to αVβ3 on CD4⁺ T cells and macrophages, facilitating viral entry and cell-to-cell spread. The gp120 V3 loop contains an RGD-like sequence that interacts with the β3 MIDAS domain. This interaction is enhanced by the binding of the viral envelope to CD4 and CCR5/CXCR4, and it promotes the formation of virological synapses between infected and uninfected cells. Additionally, HIV-1 Nef protein has been shown to downregulate surface expression of β3 integrins on infected macrophages, reducing their adhesive capacity and promoting viral dissemination. ### 5.3 Bacterial Pathogens Several bacterial pathogens exploit αVβ3 for host cell invasion: - **Yersinia pseudotuberculosis** and **Y. enterocolitica**: The invasin protein binds to αVβ3 with high affinity, triggering bacterial uptake via a zipper-like mechanism. Invasin binding activates FAK and Src, leading to actin polymerization and phagocytosis. - **Neisseria meningitidis**: The opacity-associated adhesin (Opa) proteins bind to αVβ3 on endothelial cells, facilitating bacterial transcytosis across the blood-brain barrier. This interaction is critical for the development of meningococcal meningitis. - **Staphylococcus aureus**: The fibronectin-binding protein A (FnBPA) bridges the bacterium to αVβ3 via fibronectin, promoting internalization into endothelial cells and contributing to endovascular infections. ### 5.4 Viral Immune Evasion via β3 Adenoviruses, particularly species B and D, use αVβ3 as a co-receptor for cell entry. The viral penton base protein contains an RGD motif that binds to the integrin, triggering clathrin-mediated endocytosis. Some adenoviruses also exploit β3 signaling to suppress innate immune responses: engagement of αVβ3 activates the PI3K/Akt pathway, which inhibits IRF3 phosphorylation and reduces type I interferon production, thereby promoting viral replication. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 FDA-Approved αIIbβ3 Antagonists Three αIIbβ3 inhibitors are FDA-approved for use in patients undergoing PCI and for the management of acute coronary syndromes: | Drug | Class | Mechanism | Clinical Use | |------|-------|-----------|--------------| | **Abciximab** (ReoPro) | Chimeric monoclonal antibody (c7E3 Fab) | Binds to the β3 subunit and blocks fibrinogen binding | Adjunct to PCI; reduces ischemic complications | | **Eptifibatide** (Integrilin) | Cyclic heptapeptide | Mimics the RGD/KGD sequence; reversibly inhibits αIIbβ3 | PCI and unstable angina | | **Tirofiban** (Aggrastat) | Non-peptide small molecule | Competitively inhibits fibrinogen binding to αIIbβ3 | PCI and unstable angina | **Pharmacogenomic considerations**: The *ITGB3* PlA1/PlA2 polymorphism (Leu33Pro) affects the binding affinity of abciximab. Pro33 carriers exhibit reduced abciximab binding and require higher doses to achieve equivalent platelet inhibition. Conversely, eptifibatide and tirofiban binding is unaffected by the polymorphism, making them preferable in Pro33 carriers. ### 6.2 αVβ3 Antagonists in Oncology αVβ3 is a validated target for anti-angiogenic and anti-metastatic therapy. Several agents are in clinical development: - **Cilengitide** (EMD 121974): A cyclic RGD pentapeptide that inhibits αVβ3 and αVβ5. In Phase III trials for glioblastoma, cilengitide failed to improve overall survival when added to standard chemoradiotherapy, but subgroup analyses suggested benefit in patients with low MGMT promoter methylation. - **Etaracizumab** (MEDI-522, abegrin): A humanized monoclonal antibody against αVβ3. Phase II trials in metastatic melanoma showed modest activity, with disease stabilization in ~20% of patients. - **MK-0429**: An orally bioavailable small-molecule αVβ3 antagonist. Preclinical studies demonstrated inhibition of bone metastasis in prostate cancer models. - **Lenvatinib**: A multi-kinase inhibitor that also inhibits αVβ3 signaling indirectly by downregulating integrin expression. It is FDA-approved for thyroid cancer and hepatocellular carcinoma. ### 6.3 Investigational Agents and Gene Therapy - **RGD-modified nanoparticles**: Liposomes and polymeric nanoparticles decorated with RGD peptides are being developed for targeted drug delivery to αVβ3-expressing tumors. These vehicles can deliver chemotherapeutics (e.g., doxorubicin) or siRNA specifically to tumor vasculature. - **Antisense oligonucleotides (ASOs)**: An ASO targeting *ITGB3* mRNA (IONIS-ITGB3Rx) has shown efficacy in reducing platelet aggregation in preclinical models of thrombosis. It is in Phase I trials for the prevention of arterial thrombosis. - **Gene therapy for Glanzmann thrombasthenia**: Adeno-associated virus (AAV) vectors encoding the *ITGB3* cDNA have been tested in a canine model of GT. A single intravenous injection of AAV8-ITGB3 restored platelet αIIbβ3 expression to ~20% of normal levels and corrected bleeding times for up to 2 years. Clinical trials in humans are planned. ### 6.4 Drug Resistance Mechanisms Resistance to αIIbβ3 antagonists can arise through: - **Upregulation of alternative integrins**: Platelets from patients on chronic eptifibatide therapy show increased surface expression of αVβ3, which can partially compensate for αIIbβ3 blockade. - **Conformational changes**: The high-affinity conformation of αIIbβ3 has a lower dissociation rate for eptifibatide, reducing drug efficacy. This is particularly relevant in patients with the PlA2 polymorphism. - **Hapten-induced antibodies**: Repeated exposure to abciximab can elicit anti-drug antibodies that neutralize the drug and cause thrombocytopenia. --- ## 7. Bioinformatic Resources & Database Accessions | Database | Accession / ID | Description | |----------|----------------|-------------| | **NCBI Gene** | 3690 | Gene records, genomic context, and expression data | | **Ensembl** | ENSG00000259207 | Genome annotation, transcripts, and variation | | **UniProt** | P05106 | Protein sequence, post-translational modifications, and function | | **RCSB PDB** | 1JV2, 1M1X, 2VDR, 3FCS | Crystal structures of αVβ3 and αIIbβ3 ectodomains | | **OMIM** | 173470 | Mendelian inheritance and clinical phenotypes | | **ClinVar** | ITGB3 | Pathogenic variants and clinical classifications | | **HGMD** | ITGB3 | Comprehensive mutation database (professional access) | | **STRING** | 9606.ENSP00000262601 | Protein-protein interaction network | | **BioGRID** | 112345 | Physical and genetic interactions | | **GTEx** | ITGB3 | Tissue-specific expression and eQTLs | | **Human Protein Atlas** | ENSG00000259207 | Protein expression in normal and cancer tissues | | **Gene Ontology** | GO:0004872 (receptor activity), GO:0007155 (cell adhesion), GO:0007229 (integrin-mediated signaling) | Functional annotations | | **Reactome** | R-HSA-354192 (Integrin signaling) | Pathway annotations | | **KEGG** | hsa04510 (Focal adhesion), hsa04611 (Platelet activation) | Pathway maps | | **PharmGKB** | PA338 | Pharmacogenomic annotations and drug interactions | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References 1. Bennett, J. S. (2005). Structure and function of the platelet integrin αIIbβ3. *Journal of Clinical Investigation*, 115(12), 3363–3369. https://doi.org/10.1172/JCI26989 2. Nurden, A. T., & Nurden, P. (2008). Glanzmann thrombasthenia: A review of ITGA2B and ITGB3 defects. *Journal of Thrombosis and Haemostasis*, 6(9), 1465–1473. https://doi.org/10.1111/j.1538-7836.2008.03067.x 3. Xiong, J. P., Stehle, T., Diefenbach, B., et al. (2001). Crystal structure of the extracellular segment of integrin αVβ3. *Science*, 294(5541), 339–345. https://doi.org/10.1126/science.1064535 4. Takagi, J., Petre, B. M., Walz, T., & Springer, T. A. (2002). Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. *Cell*, 110(5), 599–611. https://doi.org/10.1016/S0092-8674(02)00935-2 5. Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010). The final steps of integrin activation: The end game. *Nature Reviews Molecular Cell Biology*, 11(4), 288–300. https://doi.org/10.1038/nrm2871 6. Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M., & Fässler, R. (2008). Kindlin-3 is essential for integrin activation and platelet aggregation. *Nature Medicine*, 14(3), 325–330. https://doi.org/10.1038/nm1722 7. Desgrosellier, J. S., & Cheresh, D. A. (2010). Integrins in cancer: Biological implications and therapeutic opportunities. *Nature Reviews Cancer*, 10(1), 9–22. https://doi.org/10.1038/nrc2748 8. Gavrilovskaya, I. N., Shepley, M., Shaw, R., Ginsberg, M. H., & Mackow, E. R. (1998). β3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. *Proceedings of the National Academy of Sciences*, 95